Medical Condition News

RSS

Carnegie Mellon University awarded CURE grant by the Pennsylvania Department of Health

Pennsylvania Department of Health Executive Deputy Secretary Michael Wolf today presented a Commonwealth Universal Research Enhancement Program, or CURE, grant to Carnegie Mellon University. The $983,783 grant will be used for a two-year research project focused on cancer treatment technologies.

13 Aug 2012

CBIS initiates CS-TATI-1 GMP development plan

Cannabis Science (CBIS), a pioneering U.S. Biotech Company developing pharmaceutical to meet global public health challenges is pleased to announce the initiation of GMP development plan for CS-TATI-1 with the initial production of CS-TATI-1 to be performed in Colorado under C-GMP conditions evaluated by the FDA for initial human studies to treat HIV associated Kaposi Sarcoma.

13 Aug 2012

Researchers identify new gene in Cornelia deLange syndrome

Genetics researchers have identified a key gene that, when mutated, causes the rare multisystem disorder Cornelia deLange syndrome (CdLS). By revealing how mutations in the HDAC8 gene disrupt the biology of proteins that control both gene expression and cell division, the research sheds light on this disease, which causes intellectual disability, limb deformations and other disabilities resulting from impairments in early development.

13 Aug 2012

Prestigious $2.5M NIH grant to continue work into creation of artificial salivary glands

A research team at the Helen F. Graham Cancer Center at Christiana Care Health System and the Center for Translational Cancer Research performs a key role in a prestigious National Institutes of Health research project grant of $2.5 million to continue groundbreaking work into the creation of artificial salivary glands.

13 Aug 2012

Twelve states currently have adult obesity rate above 30%

Twelve states currently have an adult obesity rate above 30 percent, according to a new analysis released today by the Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF).

13 Aug 2012

Researchers discover gene mutations linked to spinocerebellar ataxia

A global hunt for the cause of a crippling inherited nerve disorder has found its target. The discovery opens the door for better diagnosis and treatment of this particular disease - but also for better understanding of why nerves in the brain's movement-controlling center die, and how new DNA-mapping techniques can find the causes of other diseases that run in families.

13 Aug 2012

NYU Langone offers chance to participate in lung cancer early detection study

NYU Langone Medical Center is a pioneer in lung cancer screening and offers comprehensive screening for individuals at risk for lung cancer. The NYU Langone Lung Cancer Screening Center is distinguished by its multidisciplinary approach and wealth of experience and is under the direction of the Divisions of Pulmonary Medicine, Thoracic Radiology and Thoracic Surgery.

13 Aug 2012

Latrepirdine demonstrates new potential against neurodegenerative conditions

The second of two studies on latrepirdine, recently published in Molecular Psychiatry, demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep disorders, and other neurodegenerative conditions. An international team led by Mount Sinai School of Medicine scientists found that latrepiridine, known commercially as Dimebon, reduced the level of at least two neurodegeneration-related proteins in mice.

13 Aug 2012

Epigenetic factors involved in treatment-resistance to schizophrenia drugs

Researchers at Mount Sinai School of Medicine may have discovered why certain drugs to treat schizophrenia are ineffective in some patients. Published online in Nature Neuroscience, the research will pave the way for a new class of drugs to help treat this devastating mental illness, which impacts one percent of the world's population, 30 percent of whom do not respond to currently available treatments.

13 Aug 2012

Popular class of diabetes drugs increase risk for bladder cancer

A popular class of diabetes drugs increases patients' risk of bladder cancer, according to a new study published online this month in the Journal of the National Cancer Institute.

13 Aug 2012

ALS risk markedly lower among alcohol consumers

A population-based case-control study of the rare but devastating neurological disease amyotrophic lateral sclerosis (ALS) has shown that the risk of such disease is increased among smokers, as has been shown previously. However, surprisingly, the risk of ALS was found to be markedly lower among consumers of alcohol than among abstainers.

13 Aug 2012

FDA extends PDUFA action date for NPS Gattex NDA

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that it has received a communication from the U.S. Food and Drug Administration extending the Prescription Drug User Fee Act action date for its New Drug Application for Gattex (teduglutide) by three months to December 30, 2012.

13 Aug 2012

Meritage commences OBS Phase 2 clinical trial for eosinophilic esophagitis

Meritage Pharma, Inc. announced that it has initiated a Phase 2 clinical trial to evaluate oral budesonide suspension (OBS) for the treatment of adolescents and young adults with eosinophilic esophagitis (EoE), an allergic inflammatory condition of the esophagus. EoE is a chronic disease characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation.

13 Aug 2012

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

Acorda Therapeutics, Inc. today announced top line results from a post-marketing commitment study evaluating a 5mg dose of dalfampridine-ER to improve walking in people with multiple sclerosis. The study failed to confirm efficacy of the 5mg dose.

13 Aug 2012

FDA clears Stryker’s Trevo Pro Retriever to treat acute ischemic stroke

Stryker Neurovascular announced today that its Trevo Pro Retriever has been granted 510(k) market clearance by the U.S. Food and Drug Administration. The Trevo Pro Retriever is the next generation in clot removal technology from Stryker, utilizing proprietary Stentriever Technology for optimized clot integration and retrieval in patients experiencing acute ischemic stroke.

From Stryker 13 Aug 2012

Researchers uncover how pathological cells activate themselves in chronic lymphocytic leukaemia

Researchers in the group of Prof. Dr. Hassan Jumaa, Centre for Biological Signalling Studies (BIOSS) of the University of Freiburg, Department for Molecular Immunology, have identified a new mechanism that causes immune cells to convert into malignant cancer cells.

13 Aug 2012

Insight into ubiquitin system

A faulty gene linked to a rare blood vessel disorder has led investigators to discover a mechanism involved in determining the fate of possibly thousands of proteins working inside cells.

13 Aug 2012

Radiation after lumpectomy helps prevent need for subsequent mastectomy in older women with early stage breast cancer

Contrary to clinical recommendations, older women with early stage breast cancer may want to undergo radiation after lumpectomy to help ensure that they will not need a mastectomy in the future. That is the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The findings indicate that current thinking on the risks and benefits of radiation for early stage breast cancer in older women may be inaccurate.

13 Aug 2012

Leukoaraiosis modifies brain function in the elderly

Researchers at the Mayo Clinic say a common condition called leukoaraiosis, made up of tiny areas in the brain that have been deprived of oxygen and appear as bright white dots on MRI scans, is not a harmless part of the aging process, but rather a disease that alters brain function in the elderly.

13 Aug 2012

Johns Hopkins CIDR receives NIH contract to study genetic diseases

The Johns Hopkins Center for Inherited Disease Research (CIDR) program contract, which provides up to $101 million in research funding from the National Institutes of Health (NIH) to study the genetic contribution to human diseases, has been renewed for another five years.

13 Aug 2012